Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Complications therapeutic

Provide patient education regarding causes of nausea and vomiting, avoidance of triggers, potential complications, therapeutic options, medication adverse effects, and when to seek medical attention. [Pg.305]

Electrolyte balance Disturbances of potassium homeostasis rarely complicate therapeutic barbiturate coma [92 ]. [Pg.276]

Description of Method. Fluoxetine, whose structure is shown in Figure 12.31a, is another name for the antidepressant drug Prozac. The determination of fluoxetine and its metabolite norfluoxetine. Figure 12.31 b, in serum is an important part of monitoring its therapeutic use. The analysis is complicated by the complex matrix of serum samples. A solid-phase extraction followed by an HPLC analysis using a fluorescence detector provides the necessary selectivity and detection limits. [Pg.588]

When in the late 1940 s the remarkable therapeutic effects of the glucocorticoids cortisone and hydrocortisone were discovered, new raw materials had to be developed to produce these complicated molecules, and new synthetic methods devised to convert either a 20-ketopregnane or 21-acetoxy-20-ketopregnane to the dihydroxyacetone side-chain characteristic of these corticoids. This latter challenge produced some extremely useful new organic chemical reactions, many of which have wider application outside of steroids. [Pg.128]

The separation of enantiomers is a very important topic to the pharmaceutical industry. It is well recognized that the biological activities and bioavailabilities of enantiomers often differ [1]. To further complicate matters, the pharmacokinetic profile of the racemate is often not just the sum of the profiles of the individual enantiomers. In many cases, one enantiomer has the desired pharmacological activity, whereas the other enantiomer may be responsible for undesirable side-effects. What often gets lost however is the fact that, in some cases, one enantiomer may be inert and, in many cases, both enantiomers may have therapeutic value, though not for the same disease state. It is also possible for one enantiomer to mediate the harmful effects of the other enantiomer. For instance, in the case of indacrinone, one enantiomer is a diuretic but causes uric acid retention, whereas the other enantiomer causes uric acid elimination. Thus, administration of a mixture of enantiomers, although not necessarily racemic, may have therapeutic value. [Pg.286]

Therapeutically t-PA and urokinase are the most important drugs for fibrinolytic therapy (myocardial infarction, stroke, massive pulmonary embolism). This treatment is associated with an enhanced risk of bleeding complications. [Pg.380]

MMPs for therapeutic interventions is complicated by the fact that MMPs are indispensable for normal development and physiology and by their multifunctionality, possible functional redundancy or contradiction, and context-dependent expression and activity. This complexity was revealed by previous efforts to inhibit MMP activity in the treatment of cancer patients that yielded unsatisfactory results. Doxycycline, at subantimicrobial doses, inhibits MMP activity, and has been used in various experimental systems for this purpose. It is used clinically for the treatment of... [Pg.746]

A number of inhibitors directed towards the active site of PKC have been developed [4]. Many of these have therapeutic potential and some are in clinical trials. The drug enzastaurin (LY317615) shows selectivity towards inhibiting PKC 3 and is currently in clinical trials for cancer. This drug has particular potential as a treatment for colon cancer because of the specific role ofPKC (311 in this disease (see above). A separate PKC (3 inhibitor, ruboxistaurin (LY333531) has been developed as a drug to treat the microvasculature complications of diabetes hyperactivation of both PKC (311 and PKC (31 contribute to diabetic retinopathy and microvasculature complications. [Pg.1008]

From a therapeutic point of view, it is essential to confirm the presence of bacteriuria (a condition in which there are bacteria in the urine) since symptoms alone are not a reliable method of documenting infection. This applies particularly to bladder infection where the symptoms of burning micturition (dysuria) and frequency can be associated with a variety of non-bacteriuric conditions. Patients with symptomatic bacteriuria should always be treated. However, the necessity to treat asymptomatic bacteriuric patients varies with age and the presence or absence of underlying urinary tract abnormalities. In the pre-school child it is essential to treat all urinary tract infections and maintain the urine in a sterile state so that normal kidney maturation can proceed. Likewise in pregnancy there is a risk of infection ascending from the bladder to involve the kidney. This is a serious complication and may result in premature labour. Other indications for treating asymptomatic bacteriuria include the presence of underlying renal abnormalities such as stones which may be associated with repeated infections caused by Proteus spp. [Pg.140]

GIT characteristics, either to improve or limit specific function, and thereby influence host health. However, the complex, multiple and varied nature of the combinations of phytochemicals present in plants and traditional herbal medicines has complicated efforts to better understand the specific interactions between phytochemicals and the GIT (Yuan and Lin, 2000). Phytochemicals have other applications, such as the use of guar gum as a vehicle to deliver therapeutics (Krishnaiah et al, 2001). [Pg.175]

Warfarin has been the primary oral anticoagulant used in the United States for the past 60 years. Warfarin is the anticoagulant of choice when long-term or extended anticoagulation is required. Warfarin is FDA-approved for the prevention and treatment of VTE, as well as the prevention of thromboembolic complications in patients with myocardial infarction, atrial fibrillation, and heart valve replacement. While very effective, warfarin has a narrow therapeutic index, requiring frequent dose adjustments and careful patient monitoring.15,29... [Pg.149]

Stress the importance of adherence with the treatments for CKD and associated complications, including lifestyle modifications and medications. Recommend a therapeutic regimen that is easy for the patient to accomplish. [Pg.400]

Response fluctuations occur with disease progression as the patient s dopamine reserves are depleted in the brain and as a complication of PD treatment. Motor fluctuations include delayed peak response, early wearing off, random unpredictable on-off, and freezing. Dyskinesias include chorea, dystonia, and diphasic dyskinesia. Wearing off can be visualized by imagining the therapeutic window of dopamine narrowing over time. The therapeutic window is defined as the minimum effective concentration of dopamine required to control PD symptoms (on without dyskinesia) and the maximum concentration before experiencing side effects from too much dopamine (on with dyskinesia). Early in the disease, a dose of... [Pg.476]

Design an appropriate therapeutic regimen for the management of immunosuppressive drug complications based on patient-specific information. [Pg.829]


See other pages where Complications therapeutic is mentioned: [Pg.210]    [Pg.1743]    [Pg.1884]    [Pg.197]    [Pg.210]    [Pg.1743]    [Pg.1884]    [Pg.197]    [Pg.272]    [Pg.8]    [Pg.87]    [Pg.169]    [Pg.186]    [Pg.111]    [Pg.305]    [Pg.423]    [Pg.646]    [Pg.703]    [Pg.755]    [Pg.1009]    [Pg.498]    [Pg.237]    [Pg.140]    [Pg.88]    [Pg.239]    [Pg.130]    [Pg.133]    [Pg.136]    [Pg.138]    [Pg.144]    [Pg.145]    [Pg.54]    [Pg.97]    [Pg.61]    [Pg.150]    [Pg.164]    [Pg.154]    [Pg.261]    [Pg.909]   
See also in sourсe #XX -- [ Pg.76 , Pg.77 ]




SEARCH



Complicance

Complicating

Complications

© 2024 chempedia.info